Protective effects of mefunidone on ischemia-reperfusion injury/Folic acid-induced acute kidney injury
Authors:
Open Access
- 23 November 2022
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 13, 1043945
Abstract
Renal ischemia-reperfusion injury (IRI) is one of the most common causes of acute kidney injury (AKI). It poses a significant threat to public health, and effective therapeutic drugs are lacking. Mefunidone (MFD) is a new pyridinone drug that exerts a significant protective effect on diabetic nephropathy and the unilateral ureteral obstruction (UUO) model in our previous study. However, the effects of mefunidone on ischemia-reperfusion injury-induced acute kidney injury remain unknown. In this study, we investigated the protective effect of mefunidone against ischemia-reperfusion injury-induced acute kidney injury and explored the underlying mechanism. These results revealed that mefunidone exerted a protective effect against ischemia-reperfusion injury-induced acute kidney injury. In an ischemia-reperfusion injury-induced acute kidney injury model, treatment with mefunidone significantly protected the kidney by relieving kidney tubular injury, suppressing oxidative stress, and inhibiting kidney tubular epithelial cell apoptosis. Furthermore, we found that mefunidone reduced mitochondrial damage, regulated mitochondrial-related Bax/bcl2/cleaved-caspase3 apoptotic protein expression, and protected mitochondrial electron transport chain complexes III and V levels both in vivo and in vitro, along with a protective effect on mitochondrial membrane potential in vitro. Given that folic acid (FA)-induced acute kidney injury is a classic model, we used this model to further validate the efficacy of mefunidone in acute kidney injury and obtained the same conclusion. Based on the above results, we conclude that mefunidone has potential protective and therapeutic effects in both ischemia-reperfusion injury- and folic acid-induced acute kidney injury.Keywords
Funding Information
- National Natural Science Foundation of China (81673499 82173877 82090024 82090020 82073918 82070070)
- Key Research and Development Program of Hunan Province of China (2021SK2015)
- Natural Science Foundation of Hunan Province
This publication has 50 references indexed in Scilit:
- Mefunidone ameliorates renal inflammation and tubulointerstitial fibrosis via suppression of IKKβ phosphorylationThe International Journal of Biochemistry & Cell Biology, 2016
- Ferroptosis, but Not Necroptosis, Is Important in Nephrotoxic Folic Acid–Induced AKIJournal of the American Society of Nephrology, 2016
- Double-Negative αβ T Cells Are Early Responders to AKI and Are Found in Human KidneyJournal of the American Society of Nephrology, 2016
- Mefunidone Attenuates Tubulointerstitial Fibrosis in a Rat Model of Unilateral Ureteral ObstructionPLOS ONE, 2015
- International Society of Nephrology's 0by25 initiative for acute kidney injury (zero preventable deaths by 2025): a human rights case for nephrologyThe Lancet, 2015
- Genetic deficiency of adiponectin protects against acute kidney injuryKidney International, 2013
- Folic acid induces acute renal failure (ARF) by enhancing renal prooxidant stateExperimental and Toxicologic Pathology, 2012
- Neutrophil Gelatinase-Associated Lipocalin in Acute Kidney Injury2012
- Pentoxifylline Attenuates Tubulointerstitial Fibrosis by Blocking Smad3/4-Activated Transcription and Profibrogenic Effects of Connective Tissue Growth FactorJournal of the American Society of Nephrology, 2005
- Folate Nephropathy Occurring During Cytotoxic Chemotherapy with High-Dose Folinic Acid and 5-FluorouracilRenal Failure, 1990